Intrapleural immunotherapy: An update on emerging treatment strategies for pleural malignancy
Author:
Affiliation:
1. NYU Pulmonary Oncology Research Team (NYU PORT), Division of Pulmonary, Critical Care, and Sleep Medicine NYU School of Medicine, NYU Langone Health New York New York
Funder
Mesothelioma Applied Research Foundation
Publisher
Wiley
Subject
Genetics(clinical),Pulmonary and Respiratory Medicine,Immunology and Allergy
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1111/crj.13010
Reference41 articles.
1. Pleural effusions as markers of mortality and disease severity
2. Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma
3. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial
4. Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial
5. Second or 3rd line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: Updated results of the IFCT-1501 MAPS2 randomized phase 2 trial
Cited by 13 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Krebs von den Lungen 6 (KL-6) is a novel diagnostic and prognostic biomarker in pleural mesothelioma;Lung Cancer;2023-11
2. Malignant Pleural Effusions in the Era of Immunotherapy and Antiangiogenic Therapy;Seminars in Respiratory and Critical Care Medicine;2023-06-12
3. Locoregional delivery of CAR-T cells in the clinic;Pharmacological Research;2022-08
4. Image-guided interventional radiological delivery of chimeric antigen receptor (CAR) T cells for pleural malignancies in a phase I/II clinical trial;Lung Cancer;2022-03
5. Localized Intra-Cavitary Therapy to Drive Systemic Anti-Tumor Immunity;Frontiers in Immunology;2022-02-11
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3